Simon Manning

Dr. Manning trained in England and Australia before completing his Neonatology Fellowship here in Boston. As the Director of the Perinatal Palliative Care Program he works with a team of dedicated colleagues to provide compassionate care to babies and their families. His interests include optimizing delivery of care to babies with complex medical conditions, and helping families navigate the challenges of having a baby in the Newborn intensive care unit. Dr. Manning is an Instructor in Pediatrics at Harvard Medical School.

Leadership Title

• Director, Perinatal Palliative Care Program

Clinical Interests

• Extreme Prematurity
• Neonatal Infectious Disease
• Neonatology
• Newborn Lung Disorders
• Newborn Screening
• Premature Birth

Education

Medical School

• Middlesex University School of Medicine

Residencies

• Royal Free Hospital, 1987 - 1988
• Middlesex Hospital, 1988 - 1989
• Addenbrooke's Hospital, 1989 - 1989
• Queen Elizabeth Hospital For Children, 1989 - 1990

Fellowships

• Great Ormond Street Children's Hospital, 1990 - 1990
• Royal Children's & Women's Hospital, 1990 - 1992
• Children's Hospital and Harvard Medical School, 1992 - 1995

Publications

(Pulled from Harvard Catalyst Profiles):

• Cleary RT, Sun H, Huynh T, Manning SM, Li Y, Rotenberg A, Talos DM, Kahle KT, Jackson M, Rakhade SN, Berry G, Berry G, Jensen FE. Bumetanide enhances phenobarbital efficacy in a rat model of hypoxic neonatal seizures. PLoS One. 2013; 8(3):e57148.

• Manning SM, Boll G, Fitzgerald E, Selip DB, Volpe JJ, Jensen FE. The clinically available NMDA receptor antagonist, memantine, exhibits relative safety in the developing rat brain. Int J Dev Neurosci. 2011 Nov; 29(7):767-73.

• Manning SM, Talos DM, Zhou C, Selip DB, Park HK, Park CJ, Volpe JJ, Jensen FE. NMDA receptor blockade with memantine attenuates white matter injury in a rat model of periventricular leukomalacia. J Neurosci. 2008 Jun 25; 28(26):6670-8.